CWM
INSY

Cornerstone Wealth Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Cornerstone Wealth Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,464
Closed -$400K – 1289
2018
Q3 		$400K Buy
+3,464
New +$27.6K 0.01% 987

Other funds holding INSY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Cornerstone Wealth Management's INSY Position: Q4 2018 in Review

Cornerstone Wealth Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 3,464 shares — an estimated $400K sold.

Cornerstone Wealth Management first reported a position in INSY in Q3 2018 and held it in 1 quarter. The position peaked at $400K in Q3 2018. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

  • Cornerstone Wealth Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Cornerstone Wealth Management sold 3,464 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $400K.
  • Cornerstone Wealth Management first reported a position in Insys Therapeutics, Inc. in Q3 2018 and held it in 1 quarter.
  • Cornerstone Wealth Management's Insys Therapeutics, Inc. position peaked at $400K in Q3 2018.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on Cornerstone Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.